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hilippines
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hilippines
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Background: This double-blind, controlled study
107007/NCT00344318) evaluated the immune responses of
he candidate vaccine, PHiD-CV (GlaxoSmithKline Biologi-
als), designed to protect infants against pneumococcal and
on-typeable Haemophilus inﬁuenzae diseases, following
o-administration with DTPw-HBV/Hib +OPV at 6-10-14
eeks of age (EPI schedule) in the Philippines.
Methods: 400 healthy Filipino infants 6 to 12 weeks
f age were randomized (3:1) to receive either PHiD-CV
r licensed 7vCRM vaccine (PrevenarTM/PrevnarTM) co-
dministered with DTPw-HBV/Hib +OPV. Vaccine immune
esponses were assessed one month post-dose III (22F-
nhibition ELISA, ELISA, micro-neutralization assays).
Results: For each of the pneumococcal serotypes
ommon between both vaccines, observed percentages
f infants with antibody concentration ≥0.2g/mL were
ithin the same range for both groups (PHiD-CV group:
91.2%; 7vCRM group: ≥86.3%). At least 99.6% of PHiD-CV
accinees had antibody concentrations ≥0.2g/mL against
neumococcal serotypes 1, 5 and 7F. Anti-pneumococcal
eometric mean antibody concentrations were within the
S
(
(
b
201-9712/$32.00 © 2008 Published by Elsevier Ltd.
oi:10.1016/j.ijid.2008.05.002ame range for both vaccines except for serotypes 18C
nd 19F for which higher immune responses were observed
n the PHiD-CV group. Moreover, immune responses of
ll co-administered vaccines were in line with previous
bservations, with the exception of responses against polio
irus types 1 and 3 which seemed lower in the 7vCRM
roup. Based on these immunogenicity results, PHiD-CV
ould potentially prevent 79% of IPD in Filipino infants
ompared to 62% for 7vCRM (abstract# 3.003), reﬂecting
he importance of the additional serotypes (especially 1
nd 5) for IPD in the Philippines.
Conclusions: PHiD-CV elicited high immune responses for
ach of the 10 pneumococcal vaccine serotypes in infants
accinated according to the 6-10-14 week’s schedule. No
vidence of negative immunological interference beiween
HiD-CV and co-administered vaccines was observed.
oi:10.1016/j.ijid.2008.05.003
.003
mpact Estimate of the 10-Valent Pneumococcal Non-
ypeable Haemophilus inﬂuenzae Protein D-Conjugate
accine (PHiD-CV) on Invasive Pneumococcal Disease (IPD)
n Middle East and Asian Countries
.P. Hausdorff1, F. Beckers1, R. Dagan2, N. Begg3,∗, S.
atchalian3, L. Schuerman3
GlaxoSmithKline Biologicals, Rixensart, Belgium
Soroka Med Centre and Ben-Gurion University, Beersheva,
srael
GlaxoSmithKline Biologicals, Makata City, Philippines
Background: The candidate PHiD-CV vaccine (Glaxo-
mithKline Biologicals), contains 3 additional serotypes
1, 5, 7F) in comparison to the licensed 7vCRM vaccine
PrevenarTM/PrevnarTM).
Methods: Public health impact of PHiD-CV was estimated
ased on serotype-speciﬁc vaccine effectiveness (SSVE) val-
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ues for 7vCRM1, country-speciﬁc IPD serotype distribution
and serotype-speciﬁc immunological differences between
PHiD-CV and 7vCRM when co-administered at 6-10-14 weeks
of age with DTPw-HBV/Hib and OPV vaccines in the Philip-
pines (abstract# 3.002). SSVE’s for PHiD-CV (each serotype in
common with 7vCRM and 6A) were obtained by multiplying
7vCRM SSVE’s by the ratio of the percentages of PHiD-
CV- versus 7vCRM-vaccinated children reaching a predeﬁned
immunogenicity threshold one month after 3 primary doses.
SSVE’s for 19A (both vaccines) and for 1, 5, 7F (PHiD-CV)
were set essentially equivalent to the % children achiev-
ing the threshold for each seratype. The overall impact of
each vaccine in country-j (IPD-IEoverallj) is shown in equation
1 below.
Results: Using the 0.2g/mL threshold (22F-ELISA) as
basis of comparison and applying the IPD-IE to IPD serotype
data from several countries, PHiD-CV is estimated to pre-
vent approximately 59—85% of IPD while 7vCRM would
prevent 36—75% as shown in table below. Similar results
were obtained using ELISA 0.35g/mL or OPA 1:8 as immuno-
logical thresholds for comparison. Since countries might be
using different immunization schedules or DTPa-based co-
administered vaccines; IPD-IEs were also computed using
immunogenicity data from a European study in which
PHiD-CV or 7vCRM were co-administered with DTPa-HBV-
IPV +Hib-MenC at 2-4-6 months of age. Calculated IPD-IEs
(PHiD-CV: 57—80%; 7vCRM: 36—74%) were within the same
range as those mentioned above.
Conclusions: PHiD-CV would be predicted to prevent
59—85% of IPD in children depending on the relative impor-
tance of serotypes 1, 5, 7F in the above noted Middle East
and Asian countries.
Reference
1. Whitney CG. Lancet 2006;368:1495—502.
doi:10.1016/j.ijid.2008.05.004
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Activities of Artesunate and Amodiaquine against Intesti-
nal Helminth in Children with Plasmodium falciparum
Malaria in Endemic Area
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Sagamu, Ibadan, Nigeria
2 Department of Pharmacology & Therapeutics and Institute
for Medical Research and Training, University of Ibadan,
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The activities of the antimalarial drugs- artesunate and
amodiaquine against intestinal helminth were evaluated in
l
c
T
e
al Presentations) e45
09 of 242 Nigerian children with uncomplicated Plasmod-
um falciparum malaria who had helminth before, during
nd after treatment with the two therapies. The chil-
ren were randomized to the standard dose regimens of
he drugs. Clinical recovery from malaria occurred in all
hildren. Helminth was detected in 102 patients (93.6%)
efore treatment and in another 7 patients (6.4%) after
reatment. The children treated with artesunate had sim-
lar pretreatment helminth ova load, signiﬁcantly shorter
alaria parasite clearance times (1.3 + 0.5 versus 2.8 + 1.8
, P = 0.0001), high total parasite reduction potential in 24 h
TPRP24h) (P = 0.0001) and lower geometric mean helminth
va load by day 14 (P = 0.012) following treatment than
hose treated with amodiaquine. However, helminth para-
ite excretion time was signiﬁcantly shorter in those treated
ith amodiaquine (P = 0.003). Kaplan-Meier survival curve
f cumulative probability of remaining helminth ova career
howed that by day 14 of follow-up, children treated with
rtesunate had signiﬁcant propensity to still carry helminth
va than in amodiaquine treated children (Log rank statistics
.67, df = 1, P = 0.03). These results suggest that both arte-
unate and amodiaquine not only clear malaria parasite, but
lso offer considerable anti-helminth activity that is more
ronounced with amodiaquine-an additional advantage for
ombination therapy.
oi:10.1016/j.ijid.2008.05.005
.002
ransmission Dynamics of MDR-TB and XDR-TB in Areas of
arying HIV Prevalence
.C. Victor1,∗, A. Calver2, A. Falmer1, O. Strauss1,
. Streicher1, G. Louw1, R. Johnson1, A. Trollip1, A.
ordaan1, P.D. van Helden1, R. Warren1
Stellenbosch University, Tygerberg, South Africa
Anglogold Mine, West Vaal Hospital, South Africa
Background and aim: There have been many reports
n co-infection with HIV and Tuberculosis, however, the
isease dynamics of drug-resistant Mycobacterium tubercu-
osis strains in areas of high HIV prevalence remains largely
nknown. This study aimed to investigate the population
tructure of drug-resistant strains in settings of high HIV
revalence in South Africa.
Methods: A molecular epidemiological approach (IS6110-
FLP, spoligotyping, MIRU-typing, drug-resistance genotyp-
ng, phylogenetic tree analysis) was used to study the
ynamics of drug-resistant strains in 3 settings with different
IV prevalence’s (Western Cape, Eastern Cape and a mine
n the Northern Province).
Results: Cluster analysis showed that more than 60% of
rug-resistant TB was due to the transmission of resistant
trains in the 3 study settings. A hyper transmissible drug-
esistant clone with the Beijing genotype was responsible
or the signiﬁcant increase in the number of drug-resistant
ases in the Western Cape setting over a 5 year period. Phy-
ogenetic analysis, of isolates collected in the mine setting,
oupled with contact tracing, demonstrated how MDR-
B acquired additional resistance markers (pyrazinamide,
thambutol and oﬂoxacin) in a stepwise manner despite
n excellent TB control program. This stepwise evolution
